Antimicrobial Resistance among Enteric Pathogens

  • Larry K. Pickering
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 609)

Each year diarrheal disease results in significant morbidity and mortality worldwide. In the United States diarrhea is associated with 1.5 outpatient visits, 200,000 hospitalizations and approximately 300 deaths per year. Worldwide in children under 5 years of age, over 1.5 billion diarrhea episodes and approximately 2 million deaths occur annually, although mortality due to diarrhea has been reduced significantly worldwide by oral rehydration therapy (King et al. 2003). Enteric infections generally are self-limited conditions that require fluid and electrolyte therapy, but with certain bacterial and protozoal agents, antimicrobial therapy should be considered. Antimicrobial agents should be prescribed with an appreciation of their limitations, specifically the potential for development of bacterial resistance which occurs following widespread use of antimicrobial agents in humans and animals (Johnson et al. 2006; Gallay et al. 2007). Because resistance among enteric pathogens can spread rapidly, constant monitoring of susceptibility patterns of bacterial isolates is critical for selection of appropriate antimicrobial agents for therapy when indicated (Centers for Disease Control and Prevention, NARMS 2006). The purpose of this article is to review limitations of and indications for antimicrobial therapy of enteric infections with emphasis on antimicrobial resistance.


Antimicrobial Agent Antimicrobial Therapy Hemolytic Uremic Syndrome Antimicrob Agent Enteric Pathogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aleksic S, Katz A, and Aleksic V, et al. (1993). Antibiotic resistance of Shigella strains isolated in the Federal Republic of Germany 1989–1990. Zentralbl Bakteriol, 279:484–493.PubMedGoogle Scholar
  2. American Academy of Pediatrics. (2006). Shigella infections. In Pickering LK, Baker CJ, Long SS, and McMillan JA (eds.), Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. American Academy of Pediatrics, Elk Grove Village, IL, pp. 589–591.Google Scholar
  3. Angulo FJ, Baker NL, and Olsen S. (2004). Antimicrobial use in agriculture–controlling the transfer of antimicrobial resistance in humans. Semin Pediatr Infect Dis, 2:78–85.CrossRefGoogle Scholar
  4. Bennish ML, Wasif AK, and Begum M, et al. (2006). Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae Type 1 infection in Bangladesh. CID, 42:356–62.CrossRefGoogle Scholar
  5. Bhutta ZA, Khan IA, and Shadmani M. (2000). Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother, 44:450–452.PubMedCrossRefGoogle Scholar
  6. Centers for Disease Control and Prevention. (2006). National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): 2003 Human Isolates Final Report. US Department of Health and Human Services, Atlanta, GA.Google Scholar
  7. Cheasty T, Skinner JA, and Rowe B, et al. (1998). Increasing incidence of antibiotic resistance in shigellas from humans in England and Wales: recommendations for therapy. Microb Drug Resist, 4:57–60.PubMedCrossRefGoogle Scholar
  8. Coker AO and Adefeso AO. (1994). The changing patterns of Campylobacter jejuni/coli in Lagos, Nigeria after ten years. East Afr Med J, 71:437–440.PubMedGoogle Scholar
  9. Eng JV, Marcus R, and Hadler JL, et al. (2003). Consumer attitudes and use of antibiotics. Emerg Infect Dis, 9:1128–1135.Google Scholar
  10. Engberg J, Aarestrup FM, and Taylor DE, et al. (2001). Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis, 7:24–34.PubMedCrossRefGoogle Scholar
  11. Feierl G. Wagner U, and Sixl B, et al. (2001). Epidemiology of Campylobacteriosis and development of resistance in Styria, Austria [Abstract B-15]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1–5, 2001. Int J Med Microbiol, 291(Suppl 31):9.Google Scholar
  12. Gallay A, Prouzet-Mauléon VP, and Kemph I, et al. (2007). Campylobacter antimicrobial drug resistance among humans, broiler chickens and pigs, France. Emerg Infect Dis, 13:259–266.PubMedCrossRefGoogle Scholar
  13. Gaudreau C and Gilbert H. (1998). Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob Agents Chemother, 42:2106–2108.PubMedGoogle Scholar
  14. Gaudreau C and Gilbert H. (2003). Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob Agents Chemother, 47:2027–2029.PubMedCrossRefGoogle Scholar
  15. Gaudreau C and Michaud S. (2003). Cluster of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Quebec, Canada. Clin Infect Dis, 37:131–136.PubMedCrossRefGoogle Scholar
  16. Griffin PM, Tauxe RV, and Redd SC, et al. (1989). Emergence of highly trimethoprim-sulfamethoxazole-resistant Shigella in a native American population: an epidemiologic study. Am J Epidemiol, 129:1042–1051.PubMedGoogle Scholar
  17. Guerrant RL, Gilder TV, and Steiner TS, et al. (2001). Practice guidelines for the management of infectious diarrhea. Clin Infect Dis, 32:331–350.PubMedCrossRefGoogle Scholar
  18. Gupta A, Nelson JM, and Barrett TJ, et al. (2004). Antimicrobial resistance among Campylobacter strains, United States, 1997–2001. Emerg Infect Dis, 10:1102–1109.PubMedGoogle Scholar
  19. Hakanen A, Jousimies-Somer H, and Siitonen A, et al. (2003). Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis, 9:267–270.PubMedGoogle Scholar
  20. Harnett N. (1992). High level resistance to trimethoprim, cotrimoxazole and other antimicrobial agents among clinical isolates of Shigella species in Ontario, Canada – an update. Epidemiol Infect, 109:463–472.PubMedCrossRefGoogle Scholar
  21. Helms M, Vastrup P, and Gerner-Smidt P, et al. (2002). Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis, 8:490–495.PubMedGoogle Scholar
  22. Helms M, Simonsen J, and Olsen KE, et al. (2005). Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J. Infect Dis, 191:1050–1055.PubMedCrossRefGoogle Scholar
  23. Hoge CW, Gambel JM, and Srijan A, et al. (1998). Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis, 26:341–345.PubMedCrossRefGoogle Scholar
  24. Jain SK, Gupta A, and Glanz B, et al. (2005). Antimicrobial-resistant Shigella sonnei. Limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility. Pediatr Infect Dis J, 24:494–497.PubMedCrossRefGoogle Scholar
  25. Johnson JR, Kuskowski MA, and Menard M, et al. (2006). Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status. J. Infect Dis, 194:194–198.Google Scholar
  26. King CK, Glass R, and Bresee JS, et al. (2003). The management of acute gastroenteritis in children: oral rehydration, maintenance, and nutrition therapy: 2003 CDC guidelines. MMWR, 52(RR-16):1–16.PubMedGoogle Scholar
  27. Krausse R and Ullmann U. (2003). In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother, 47:2946–2950.PubMedCrossRefGoogle Scholar
  28. Li, CC, Chiu CN, and Wu JL, et al. (1998). Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis, 30:39–42.PubMedCrossRefGoogle Scholar
  29. Magee JT, Pritchard EL, and Fitzgerald KA, et al. (1999). Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996–1998. BMJ, 319:1239–1240.PubMedGoogle Scholar
  30. Melby KK and Mannsäker T. (2001). Antibiotic sensitivity pattern of Campylobacter spp recovered over a ten year period from patients residing in Oslo Area. [Abstract B-17]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1–5, 2001. Int J Med Microbiol, 291(Suppl 31):9.Google Scholar
  31. Molbak K, Gerner-Smidt P, and Wegener HC. (2002). Increasing quinolone resistance in Salmonella enterica serotype enteritidis. Emerg Infect Dis, 8:514–515.PubMedGoogle Scholar
  32. Murray BE. (1989). Problems and mechanisms of antimicrobial resistance. Infect Dis Clin North Am, 3:423–439.PubMedGoogle Scholar
  33. Nachamkin I, Ung H, and Li M. (2001). Fluoroquinolone resistant Campylobacter jejuni in Philadelphia, 1982–2000. [Abstract B-06]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1–5, 2001. Int J Med Microbiol, 291(Suppl 31):6.Google Scholar
  34. Nelson JM, Smith KE, and Vugie DJ, et al. (2004). Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J. Infect Dis, 190:1150–1157.PubMedCrossRefGoogle Scholar
  35. Ohara T, KojioS, and Taneike I, et al. (2002). Effects of azithromycin on Shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother, 46:3478–3483.PubMedCrossRefGoogle Scholar
  36. Replogle ML, Fleming DW, and Cieslak PR. (2000). Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis, 30:515–519.PubMedCrossRefGoogle Scholar
  37. Saenz Y, Zarazaga M, and Lantero M, et al. (2000). Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997–1998. Antimicrob Agents Chemother, 44:267–271.PubMedCrossRefGoogle Scholar
  38. Safdar N, Said A, and Gangnon Re, et al. (2002). Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli 1057:H7 enteritis. A meta-analysis. JAMA, 288:996–1000.PubMedCrossRefGoogle Scholar
  39. Sanchez C, Garcia-Restoy E, and Garau J, et al. (1993). Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis, 168:1304–1307.PubMedGoogle Scholar
  40. Sanders JW, Isenbarger DW, and Walz SE, et al. (2002). An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg, 67:533–538.PubMedGoogle Scholar
  41. Sirinavin S and Garner P. (2000). Antibiotics for treating Salmonella gut infections. Cochrane Database Syst Rev, (2) CD001167.Google Scholar
  42. Smith KE, Besser JM, and Hedberg CW, et al. (1999). Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. N Engl J Med, 340:1525–1532.PubMedCrossRefGoogle Scholar
  43. Stevenson JE, Gay K, and Barrett TJ, et al. (2007). Increase in nalidixic acid resistance among non-typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother, 51:195–97.PubMedCrossRefGoogle Scholar
  44. Talsma E, Goettsch WG, and Nieste HL, et al. (1999). Resistance in Campylobacter species: increased resistance to fluoroquinolones and seasonal variation. Clin Infect Dis, 29:845–848.PubMedCrossRefGoogle Scholar
  45. Taylor DE and Chang N. (1991). In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Antimicrob Agents Chemother, 35:1917–1918.PubMedGoogle Scholar
  46. Threlfall EJ and Ward LR. (2001). Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis, 7:448–450.PubMedCrossRefGoogle Scholar
  47. Vahaboglu H, Fuzi M, and Cetin S, et al. (2001). Characterization of extended-spectrum beta-lactamase (TEM-52)-producing strains of Salmonella enterica serovar typhimurium with diverse resistance phenotypes. J Clin Microbiol, 39:791–793.PubMedCrossRefGoogle Scholar
  48. van Duijkeren E, Wannet WJ, and Houwers DJ, et al. (2003). Antimicrobial susceptibilities of Salmonella strains isolated from humans, cattle, pigs, and chickens in the Netherlands from 1984 to 2001. J Clin Microbiol, 41:3574–3578.PubMedCrossRefGoogle Scholar
  49. Varma J, Molbak K, and Barrett TJ. (2005). Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis, 191:554–561.PubMedCrossRefGoogle Scholar
  50. Villa L, Mammina C, and Miriagou V, et al. (2002). Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy. J Clin Microbiol, 40:2662–2665.PubMedCrossRefGoogle Scholar
  51. Wedel S, Bender J, and Leano F, et al. (2005). Antimicrobial-drug susceptibility of human and animal Salmonella typhimurium, Minnesota, 1997–2003. Emerg Infect Dis, 11:1899–1906.PubMedGoogle Scholar
  52. World Health Organization. (1999). Containing Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland, February 4–5.Google Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Larry K. Pickering
    • 1
  1. 1.Senior Advisor to the DirectorNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and PreventionAtlanta

Personalised recommendations